Sponsors (4)
The bill seeks to accelerate development, review, and VA delivery of psychedelic, ibogaine, and other breakthrough therapies—potentially speeding patient access and spurring research—but does so at the cost of increased safety/diversion risks, added administrative and taxpayer expense, privacy and legal uncertainties, and incentives that may distort research priorities.
Patients with serious mental illness and substance-use disorders (including veterans) could gain much faster access to emerging psychedelic, ibogaine, and other breakthrough therapies because the bill shortens rescheduling, review, quota, and Right-to-Try timelines and funds pilots and trials.
Veterans would see improved VA coordination, a designated senior official, competency-based clinician training, and program oversight, which should increase safe, organized delivery of novel therapies within VA healthcare.
Developers, researchers, and manufacturers get clearer regulatory pathways and new incentives (e.g., rescheduling tied to FDA phase 3 approvals, vouchers, quota rules, and statutory definitions) that reduce some business uncertainty and encourage investment in priority treatments.
Patients, communities, and clinicians face increased safety and diversion risks because accelerated rescheduling, faster FDA/DEA reviews, expanded access to Schedule I investigational drugs, and quota ramp-ups can outpace thorough abuse-potential review and control measures.
Taxpayers, federal agencies, VA, FDA, DEA, clinicians, and health systems will incur substantial new administrative, compliance, hiring, reporting, and enforcement costs to implement training, credentialing, expedited reviews, reporting, registrations, and data-sharing requirements.
Patients (including veterans) risk privacy and confidentiality harms because the bill increases interagency and state/tribal data sharing of sensitive clinical and pilot-program data, and deidentification/legal protections may be insufficient in practice.
Based on analysis of 12 sections of legislative text.
Speeds rescheduling and regulatory pathways for psychedelics (including ibogaine), creates DEA special registration for right‑to‑try administration, establishes an FDA priority‑review voucher pilot, and funds HHS/VA research and program partnerships.
Official title: To accelerate the development of, and access to, psychedelic drugs that could save lives and reverse the crisis of serious mental illness in the United States, and for other purposes.
Introduced June 30, 2026 by Morgan Luttrell · Last progress June 30, 2026
Directs faster federal scheduling and regulatory pathways for psychedelic and related drugs (notably ibogaine) intended to treat serious mental illness, creates a FDA priority-review voucher pilot for high-priority products, and builds federal programs to support clinical trials, data sharing, and state partnerships. It requires administrative changes at DOJ/DEA, HHS/FDA, the VA, and ARPA-H/NIH to enable research, clinical use under ‘‘right to try,’’ workforce readiness, and faster supply‑chain and quota adjustments. Establishes deadlines for rescheduling reviews (including a 60‑day ibogaine review), sets up a special DEA registration for physicians to administer Schedule I investigational drugs under right‑to‑try, mandates VA reporting and staffing for emerging therapies (including psychedelic‑assisted care), creates a National Health Priority Review Voucher pilot, and funds/state‑partner programs to accelerate trials, data sharing, and real‑world evidence generation to support FDA evaluation and approval.